In this regard it should be mentioned that both, the bladder cancer and melanoma study showed elevated expression of SLAMF7 on tumor antigen-specific CD4+ CTL (146, 191) and that targeting SLAMF7 with agonistic antibodies enhanced the cytotoxic activity of CD4+ T cells (146). Here, SLAMF7 is linked to urinary bladder cancer.